UK Named Patient Supply to GCC
UK Named Patient
Medicines
to GCC Hospitals.
Euro Biom is an MHRA WDA-licensed wholesaler trading exclusively in UK-licensed medicines, supplied for named-patient import to hospitals across Saudi Arabia, UAE, Qatar, Kuwait, Bahrain and Oman. We support the import routes used with SFDA, EDE, MOPH Qatar, MoH Kuwait, NHRA Bahrain and MoH-DGPA Oman, with UK export documents to support the buyer's application.
MHRA WDA Licence No. WDA(H) 59239GCC Named Patient Import Routes Supported
Same-day response to every enquiry · Mon-Fri 09:00-18:00 GMT · WhatsApp us
Why GCC Named Patient Is Different
Five GCC-Specific Failure
Modes on Named Patient Supply.
Modes on Named Patient Supply.
GCC named patient supply is not a regional version of the UK domestic pathway. Post-Brexit MHRA documentation, hospital ethics committee variability across Riyadh, Doha, Abu Dhabi and Kuwait City, regional pricing controls, multi-country shortage rotation and 50 degree summer cold chain all create risks that GCC hospital procurement teams must work around.
Post-Brexit MHRA Paperwork
The MHRA issues UK Certificates of Pharmaceutical Product on application by the marketing authorisation holder. Incomplete document packs can delay review by the destination regulator.
Hospital Ethics Committee Variability
Hospitals run different ethics committee processes for named patient justification. What is accepted in Riyadh may need restructuring for Doha, so the prescriber or hospital should prepare its own summary.
Regional Pricing Controls
GCC regulators and payers can benchmark prices against reference markets, so buyers should check what price evidence their application needs.
Shortage Rotation Across Distributors
When a specialty line goes short, buyers sourcing from rotating UK suppliers should verify MHRA WDA status and chain of custody before accepting any pack.
50°C Summer Cold Chain
Summer ambient in Riyadh, Kuwait City and Abu Dhabi can exceed 48°C, so packaging suited to European conditions may not hold.
The Euro Biom Solution
Named patient supply
for the GCC.
for the GCC.
Euro Biom supplies UK-licensed medicines for the buyer's named patient import route. Euro Biom supplies UK product documents; the buyer manages the special use pathway and ethics submission. UK source documentation is supplied to support the buyer's special use authorisation application to SFDA, EDE, DHA, MOPH Qatar, MoH Kuwait or NHRA Bahrain.
Shipments leave under MHRA WDA(H) 59239 with a GDP documentation pack and, for temperature-sensitive lines, a temperature logger. A GDP documentation pack accompanies consignments of oncology and paediatric specialty named-patient import supply.
GCC Regulator Coverage
Saudi Arabia: SFDA Special Access route. UAE: EDE federal special import, or DHA Dubai and DOH Abu Dhabi special permits. Qatar: MOPH Special Use Committee. Kuwait: special permit with a mandatory local agent. Bahrain: NHRA import route for products not yet registered. Oman: MoH-DGPA special import. The buyer should confirm any hospital committee step locally.
MHRA WDA Authorised UK-Licensed Medicines Only GCC Named Patient Import Support
"GCC named patient is not a paperwork problem alone. It is a regulator stack problem. We supply UK-side documents to support named-patient import routes across six GCC regulators."
GCC Named Patient Therapeutic Lanes
Four Therapeutic Lanes,
Highest GCC Named Patient Demand.
Highest GCC Named Patient Demand.
GCC hospitals concentrate named patient demand in a defined cluster of therapeutic areas where local registration is absent, slow or commercially unattractive for the marketing authorisation holder. Euro Biom sources through the UK licensed supply chain.
01
Oncology and Paediatric Medicines
Targeted oncology therapies and specialist cancer medicines not yet registered with SFDA, EDE or MOPH Qatar, alongside UK-licensed oral paediatric medicines where no locally registered alternative exists and GCC consanguinity rates drive elevated demand. 2-8°C shipping where required, with the UK product documents included.
02
Diabetes and Endocrinology Medicines
Oral and other non-injectable UK-licensed diabetes and endocrinology specialty medicines not held in routine GCC distributor catalogues, for hospital pharmacies across the GCC, for the buyer's named-patient import route. Insulin and GLP-1 injectable therapies fall outside Euro Biom's WDA(H) 59239 scope and are not supplied.
03
Autoimmune and Specialty Medicines
Oral immunosuppressants, JAK inhibitors and other UK-licensed oral autoimmune agents where the destination country marketing authorisation is pending or not held, supplied to hospital pharmacies across the GCC under each country's named-patient import pathway.
04
Paediatric Specialty and Early Access
Paediatric specialty formulations, including UK-licensed oral medicines, for teaching and referral hospitals in the region. Supply of UK-licensed medicines into a buyer-held early access programme in the destination market. HIV post-exposure prophylaxis and rare antivirals for tertiary infectious disease centres.
How We Ship UK to GCC Named Patient
Four stages, with chain-of-custody documentation
from UK dispatch to the destination importer.
Each stage of a GCC-bound named patient shipment is arranged and documented. The output is a documentation pack alongside the medicine, to support the buyer's submission to SFDA, EDE, DHA, MOPH Qatar, MoH Kuwait or NHRA Bahrain and the receiving hospital ethics or therapeutics committee.
Stage 01
01
UK GDP Pickup
Product is purchased through the UK licensed supply chain and held at the contract storage site under GDP. 2-8°C medicines are shipped from the contract storage site in temperature-controlled packaging with a data logger, arranged with specialist carriers.
Stage 02
02
Documentation Pack
Where available: CPP, batch release documents, MA verification, GMP certificate and halal certificate, plus our MHRA WDA letter. The prescriber or hospital prepares the ethics-committee clinical summary. Documents shared with the buyer's importer before dispatch.
Stage 03
03
Air Freight from Heathrow
Air freight to the destination airport via a specialist pharmaceutical forwarder. Documents are shared in advance to support inspection on arrival.
Stage 04
04
Importer Handover
Destination customs clearance is handled by the buyer's licensed importer under the destination-country named patient or shortage route.
Six GCC Country Routes
One Documentation Spine,
Six Regulator Pathways.
Six Regulator Pathways.
Each GCC state runs its own special use authorisation regime, ethics committee structure and import broker pattern. Euro Biom can supply the UK-side documents available for the product to support each of the six GCC import routes.
🇸🇦
Saudi Arabia
SFDA Special Access Route
The hospital or local agent applies to SFDA for a medicine not registered in Saudi Arabia. Buyers should confirm with NUPCO and SFDA how localisation rules apply to named patient import, drug shortage and rare disease supply. Halal certification can be requested from the manufacturer where available.
Primary hospital types: national oncology referral centres, MoH regional and National Guard facilities
🇦🇪
United Arab Emirates
EDE federal plus DHA Dubai and DOH Abu Dhabi
EDE federal special import for federal facilities, and DHA Dubai or DOH Abu Dhabi special permits for emirate-specific hospitals. Each pathway demands its own UAE-specific documentation, and Euro Biom coordinates the UK-side documents for each.
Primary hospital types: federal and emirate-level government hospitals, private tertiary centres
🇶🇦
Qatar
MOPH Special Use Committee
MOPH Qatar Special Use Committee approval for named patient import of UK-licensed medicines not yet registered in Qatar. Hospital committee steps should be confirmed with the hospital. Paediatric cases at Sidra Medicine may follow a separate route, which the buyer should confirm with MOPH.
Primary hospital types: national referral hospital and paediatric specialty centre
🇰🇼
Kuwait
Special Permit With a Mandatory Local Agent
Kuwait Drug and Food Control Authority special permit, with a mandatory local agent.
Primary hospital types: national oncology referral centre and Ministry of Health regional hospitals
🇧🇭
Bahrain
NHRA Import Route
National Health Regulatory Authority import route for products not yet registered. Approval timing and any hospital ethics step should be confirmed with NHRA case by case.
Primary hospital types: tertiary care referral hospital and defence health facilities
🇴🇲
Oman
MoH-DGPA Special Import
Ministry of Health Directorate General of Pharmaceutical Affairs special import authorisation.
Primary hospital types: academic teaching hospital and national referral hospital
Where GCC Named Patient Demand Concentrates
Eight Therapeutic Areas
With GCC Named Patient Demand.
With GCC Named Patient Demand.
Named patient demand in the GCC concentrates in a defined cluster of specialty and rare disease therapeutic areas. Euro Biom can support enquiries across all of the following.
Oncology Specialty
Oral targeted therapies and specialist UK-licensed oncology medicines for tertiary oncology referral centres across the GCC.
Rare Disease Therapies
UK-licensed non-biologic medicines for rare conditions. GCC consanguinity rates drive elevated demand, especially paediatric.
Diabetes and Endocrinology
Oral diabetes and endocrinology specialty medicines for hospitals.
Autoimmune Specialty
Oral immunosuppressants and other oral autoimmune medicines not registered locally, supplied for named-patient import.
Paediatric Specialty
UK-licensed oral medicines and paediatric formulations, where non-biologic, for paediatric referral hospitals in the GCC.
Early Access Programmes
UK-licensed medicines awaiting commercial registration in the destination country, supplied into the buyer's named-patient import route.
HIV-PEP and Rare Antivirals
Post-exposure prophylaxis and specialist antivirals for tertiary infectious disease centres.
Haematology and Other
UK-licensed haematology medicines and other specialty lines within our licence scope.
GCC Named Patient Documentation Pack
Each GCC consignment is supported by a documentation pack.
GCC regulator presentation and the receiving hospital ethics or therapeutics committee handoff each require a defined documentation set. SFDA, EDE, DHA, MOPH Qatar, MoH Kuwait, NHRA and MoH-DGPA each look for slightly different fields, but the pack below lists documents that may support a consignment, subject to availability from the manufacturer or issuing body.
Submit a GCC Named Patient Enquiry →Same-day response · WhatsApp us directly
1
UK MHRA Certificate of Pharmaceutical Product
CPP issued by MHRA confirming UK marketing authorisation. Commonly requested for import.
2
Manufacturer Batch Release Certificate
Manufacturer batch documentation, where the manufacturer makes it available, showing batch number, expiry and manufacturing site.
3
Marketing Authorisation Verification
UK MA reference for the product, to support the buyer's named patient application.
4
GMP Certificate for Manufacturing Site
Good Manufacturing Practice certificate for the manufacturing site, where the manufacturer makes one available.
5
Halal Certificate Where Applicable
Halal certification for products containing animal-derived excipients, where the buyer or its hospital pharmacy asks for it. Confirm the requirement with the destination regulator.
6
MHRA WDA(H) 59239 Holder Letter
Letter on Euro Biom letterhead confirming WDA holder status. Verifiable on the MHRA register.
7
Data Logger Output
Where a data logger travels with the shipment, its trace is supplied for temperature-sensitive UK-licensed medicines.
8
Ethics Committee Clinical Summary
The prescriber or hospital prepares the ethics-committee summary; Euro Biom supplies the UK product documents.
GCC Named Patient Supply, Shipped from London.
Tell us the medicine, the GCC destination and the hospital. We respond the same working day with pricing, availability, freight options and the export documents available for each line. A GDP documentation pack accompanies consignments.
GCC Named Patient FAQ
UK to GCC Named Patient
Supply, Explained.
Supply, Explained.
Common questions from GCC hospital procurement teams and licensed importers sourcing named patient medicines from the UK.
What is named patient medicine supply to the GCC?
Named patient supply is the destination country's regulated import pathway for a medicine not registered in that market, supplied for an identified patient in a GCC hospital where no locally registered alternative is available. Each GCC country runs its own route: SFDA Special Access in Saudi Arabia, EDE federal special import in the UAE, MOPH Special Use Committee in Qatar, a special permit in Kuwait, the NHRA import route in Bahrain and MoH-DGPA in Oman. Euro Biom holds MHRA WDA(H) 59239, sources through MHRA-authorised UK channels, and arranges 2-8°C shipping through specialist carriers where needed, with UK product documents.
Which GCC hospitals use named-patient import routes?
Named-patient import demand comes mainly from tertiary referral and specialty hospital pharmacies across the six GCC states. Saudi Arabia: national oncology referral centres, MoH regional and National Guard facilities. UAE: federal and emirate-level government hospitals, private tertiary centres. Qatar: the national referral hospital and its paediatric specialty centre. Kuwait: the national oncology referral centre and Ministry of Health regional hospitals. Bahrain: the tertiary care referral hospital. Oman: the national academic teaching hospital.
How is GCC named patient supply different from UK domestic named patient?
UK supply of unlicensed specials falls under Regulation 167 of the Human Medicines Regulations 2012 and is outside Euro Biom's scope. GCC named patient is an import route for a UK-licensed product, with three layers, a destination-country regulator special use authorisation, a hospital ethics committee or therapeutics committee approval, and a shipping and customs pathway into the destination country. Documentation requirements are heavier and timelines longer. Euro Biom's role is the UK-licensed wholesale and export end only, with documentation packs to support the buyer's application to each GCC regulator.
Does NUPCO localisation in Saudi Arabia block named patient imports?
NUPCO 2026 localisation rules apply to routine national tenders for products with locally manufactured equivalents. Buyers should confirm with NUPCO how named patient import, shortage cases and therapies with no local equivalent are treated. Euro Biom's Saudi Arabia offer focuses on named-patient import and shortage supply for SFDA-registered importers and hospitals.
What documentation does Euro Biom provide for GCC named patient supply?
Consignments are supported by the documents available for the product, such as a Certificate of Pharmaceutical Product where issued, manufacturer batch documentation where the manufacturer makes it available, marketing authorisation verification, GMP evidence for the manufacturing site, an MHRA WDA holder letter on Euro Biom letterhead and, for temperature-sensitive lines, a temperature logger record. The prescriber or hospital prepares the ethics-committee summary. Halal certification can be requested from the manufacturer where available.
How fast can Euro Biom ship a named patient medicine to a GCC hospital?
Transit time depends on stock availability, documentation and destination customs clearance. We give an estimate at quotation.
What therapeutic areas have the highest named patient demand in the GCC?
Oncology oral targeted therapies; UK-licensed oral paediatric medicines; oral diabetes and endocrinology specialty medicines for the high-prevalence GCC diabetes population; oral autoimmune medicines not registered locally; UK-licensed medicines awaiting registration in the destination country; HIV post-exposure prophylaxis and rare antivirals; and paediatric specialty formulations. Euro Biom can source UK-licensed medicines in these categories through the UK licensed supply chain, within licence scope.
Related Resources
Further reading for GCC hospital procurement teams, SFDA-registered importers, federal UAE buyers and Ministry of Health Special Use Committee staff.
Service
UK Named-Patient Import Supply Hub
View UK service →
Pillar
UK Pharmaceutical Exporter to GCC
View GCC pillar →
Pillar
UK Pharmaceutical Supplier to MENA
View MENA pillar →
Cold Chain
UK Cold Chain Pharma Supply to Saudi Arabia
View Saudi cold chain →
Specialist Supply
Hard-to-Source & Locally Unregistered Medicines
View hard-to-source supply →
GCC Supply
UK Diabetes Medicine Supply to the GCC
View diabetes supply →
Cold Chain
UK Cold Chain Pharma Supply to UAE
View UAE cold chain →
Cold Chain
UK Cold Chain Pharmaceutical Export
View cold chain export →
GCC
UK Pharmaceutical Exporter to GCC
View GCC exports →
Country
UK Pharmaceutical Exporter to Saudi Arabia
View Saudi country page →
Country
UK Pharmaceutical Exporter to UAE
View UAE country page →
Country
UK Pharmaceutical Exporter to Qatar
View Qatar country page →
Country
UK Pharmaceutical Exporter to Kuwait
View Kuwait country page →
Country
UK Pharmaceutical Exporter to Bahrain
View Bahrain country page →
Country
UK Pharmaceutical Exporter to Oman
View Oman country page →
Guide
Named Patient Imports UK: Hospital Sourcing Guide
Read full guide →
Guide
Saudi Vision 2030 NUPCO Localisation Impact
Read NUPCO guide →
Guide
SFDA Drug Registration Guide for UK Exporters
Read SFDA guide →
Guide
UAE Import Permits 2026 Guide
Read UAE guide →
Guide
Qatar MOPH Pharmaceutical Import Process
Read MOPH guide →
Services
Full Range of Euro Biom Pharmaceutical Services
View services →
Compliance
MHRA WDA Documentation and GDP Standards
View compliance →
Contact
Submit a GCC Named Patient Enquiry
Contact us →
Request a quote
Get a tailored quote: Named Patient Medicines to GCC
Tell us what you need and our team responds the same working day. UK-licensed, MHRA WDA(H) 59239, verify on the MHRA register.